Correction: A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.

IF 4.6 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Frontiers in Endocrinology Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI:10.3389/fendo.2025.1663787

David Aristizábal-Colorado, David Corredor-Rengifo, Santiago Sierra-Castillo, Carolina López-Corredor, David-Alexander Vernaza-Trujillo, Danilo Weir-Restrepo, Juan S Izquierdo-Condoy, Esteban Ortiz-Prado, Jorge Rico-Fontalvo, Juan-Esteban Gómez-Mesa, Alin Abreu-Lomba, Wilfredo-Antonio Rivera-Martínez

引用次数: 0

Abstract

[This corrects the article DOI: 10.3389/fendo.2025.1605746.].

查看原文本刊更多论文

修正：2型糖尿病和心血管疾病的十年进展：SGLT2抑制剂和GLP-1受体激动剂的进展-一项全面的综述。

[此更正文章DOI: 10.3389/ fend.2025 .1605746.]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Endocrinology Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

5.70

自引率

9.60%

发文量

3023

审稿时长

14 weeks

期刊介绍： Frontiers in Endocrinology is a field journal of the "Frontiers in" journal series. In today’s world, endocrinology is becoming increasingly important as it underlies many of the challenges societies face - from obesity and diabetes to reproduction, population control and aging. Endocrinology covers a broad field from basic molecular and cellular communication through to clinical care and some of the most crucial public health issues. The journal, thus, welcomes outstanding contributions in any domain of endocrinology. Frontiers in Endocrinology publishes articles on the most outstanding discoveries across a wide research spectrum of Endocrinology. The mission of Frontiers in Endocrinology is to bring all relevant Endocrinology areas together on a single platform.